Feeds:
Posts
Comments

Posts Tagged ‘The Lancet Oncology’

CANCER CONSULTANTS: Clodronate reduces the risk of death by 23% in men with metastatic prostate cancer, according to the results of a study published in The Lancet Oncology. Clodronate belongs to a class of drugs called bisphosphonates, which are used to treat or prevent bone complications. READ MORE>

Read Full Post »

E-CANCER MEDICAL SCIENCE: Oral bone loss drug sodium clodronate improves overall survival in men with advanced prostate cancer, but does not reduce the risk of death in men with localised disease, according to trial results published in The Lancet Oncology. READ MORE>

Read Full Post »